View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 13, 2021

Resverlogix to initiate Covid-19 therapy trial in Canada

The trial intends to enrol 100 adult patients hospitalised with Covid-19 at various sites in Brazil and Canada.

Resverlogix has obtained approval from the Health Research Ethics Board (HREB) – Biomedical Panel at the University of Alberta in Canada to commence a clinical trial of its new therapy, apabetalone (RVX-208), for Covid-19 in the country.

With the approval, the company can now start enrolling subjects in the trial.

An epigenetic small molecule, or gene-regulating therapeutic candidate, apabetalone can selectively inhibit bromodomain and extra-terminal (BET).

It aids in disease prevention by regulating gene expression by turning on and/or off genes.

The open-label, exploratory trial will analyse the safety and effect on the clinical course of oral apabetalone in Covid-19 patients in the hospital.

It plans to enrol a total of 100 adult subjects aged 18 years and above at several trial centres in Canada and Brazil.

Subjects will be given either twice-daily doses of apabetalone for up to four weeks plus standard of care or standard of care alone.

The change in the World Health Organization Ordinal Scale for Clinical Improvement will be the trial’s primary goal.

Resverlogix president and CEO Donald McCaffrey said: “The ethics board approval is an important step towards bringing apabetalone to market to help fight the ongoing Covid-19 pandemic.

“The approved trial design closely follows the World Health Organization’s blueprint for best practices in Covid-19 clinical trials and meets all requirements to safely and ethically evaluate apabetalone as a potential new therapy.”

The company noted that apabetalone is the only therapy of its class to possess a well-established safety record in human trials, with more than 4,200 patient-years on drugs across ten trials.

According to the studies, apabetalone can potentially target SARS-CoV-2 with a peculiar dual-mechanism of preventing viral entry to cells and its replication, and by stopping runaway inflammatory reactions.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU